Edgewise Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Edgewise Therapeutics (EWTX) with a Buy rating and $42 price target The clinical-stage biotechnology company focused on developing orally delivered small molecule inhibitors for severe muscle diseases is currently advancing two candidates on its clinical pipeline: sevasemten, which is designed to protect contraction-induced muscle damage caused by dystrophinopathies, including Becker muscular dystrophy and Duchenne muscular dystrophy, and EDG-7500 for both obstructive and non-obstructive forms of hypertrophic cardiomyopathy. The firm sees potential for sevasemten to become the first approved drug for BMD, and an adjuvant for DMD, and for EDG-7500 as “a valid alternative” to cardiac myosin inhibitor-mediated excessive heart function reduction.